ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
